The U.S. Food and Drug Administration approved United Therapeutics Corporation’s Tyvaso (treprostinil) Inhalation Solution for the treatment of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.
On the back of a $135 million public offering in February, rare disease gene therapy company Krystal Biotech Inc. launched subsidiary Jeune Inc. to promote gene therapies for aesthetic skin conditions.
Med Ad News spoke with Klick Health’s Amy Gomez, senior VP, diversity strategy, and Samantha Dolin, executive creative director, about the agency’s “Rise Above COVID” cross-cultural marketing campaign for the ACTIV-2 trial.
The U.S. Food and Drug Administration approved Oncopeptides AB’s Pepaxto (melphalan flufenamide) in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.
In a historical move, healthcare investor giant Deerfield Management entered a second partnership with one of its academic collaborators, investing up to $130 million over the next ten years into Dana-Farber Cancer Institute to advance the development of new therapeutics and diagnostic tools for cancer patients.
IPG Health Germany won the communications account around the new women’s health portfolio of pharmaceutical manufacturer DR. KADE Health Care.
Flagship Pioneering launched a new company called Inzen Therapeutics, which will discover and develop a new class of medicines based on a new area of biology that will provide new therapeutic approaches to multiple types of diseases.
RNAi-focused Atalanta Therapeutics launched with $110 million in combined Series A funding and collaboration deals with Genentech and Biogen to address diseases related to the central nervous system, including Huntington’s, Alzheimer’s and Parkinson’s diseases.
Humanigen Inc. and EVERSANA announced that they are partnering to make lenzilumab available to hospitalized and hypoxic Covid-19 patients in the event that an Emergency Use Authorization is issued from the U.S. Food and Drug Administration and subsequent BLA.
BioSpace presented the NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
